Welcome to LifeSciences2030
Investing in the future of health.
Health is the new wealth.
We support health and life science start-ups maturing into successful companies
Our mission is to empower those entrepreneurs and scientific teams to create value and transform our approach to health care. It’s time to change the world.
Fund Focus and Facts
Pharma / Biotech / Digital Health / Med Tech
Seed to Later Stage
DACH / German-speaking Europe
Investment team with strong clinical, scientific and entrepreneurial backgrounds
International and highly experienced network
- Apps & platforms
- Health empowerment concepts
- Hardware
- Virtual medicine
- Personalized medicine
- Al (artificial intelligence)
- Clinical data platforms
- Oncology therapeutics & diagnostics
- Innovative formulation platforms
- Anti-infective drugs
Invest in health.
Year
2019
Global Med-Tech
Valued at some $430B in 2019
2022
9% growth
Generic pharmaceuticals market was valued at about $217B in 2018 and is expected to grow to around $309B at an annual growth rate of more than 9% through 2022
2023
$1.6 trillion
Global pharmaceutical industry will be worth $1.6 trillion with a CAGR of 6%
2024
Oncology by $233B
Oncology as the no. 1 therapy will reach $233B with 12.2% CAGR. Prescription drug sales between 2019 and 2024 are projected to have a positive CAGR of 6.9% with sales expected to reach $1.18 trillion.
2025
Biotechnology at $755B
Biotechnology market size surpassed $417B in 2018 and is projected to achieve a value of $755B in 2025 at 8.3% CAGR
2025
Biotechnology at $755B
Biotechnology market size surpassed $417B in 2018 and is projected to achieve a value of $755B in 2025 at 8.3% CAGR
Be part of it!
Our Strategic Partners
Health Hub Tirol
Our mission is to empower those entrepreneurs and scientific teams to create value and transform our approach to health care. It’s time to change the world.
Contact us
About us
Our team has an impressive track record in industry knowledge, competition & regulatory environment, and high-level skills in financing, restructuring, growing and performance improving.
Cornelia Beier
30 years of experience in the pharmaceutical & biotech industries (BMS, Takeda, Pharmacia, etc.)
- Founding partner and CEO CB one Holding GmbH
- Founding partner at leon-nanodrugs GmbH
- Founder health2030 platform
- Co-founder of AI-company Oncology World
- Partner of an international CRO network
- Founder of one of the leading pharmaceutical PR agency in Germany (Kohtes Klewes communication medical – today Ketchum PLEON GmbH)
Berthold Baurek-Karlic
15+ years of professional investment experience, a venture capital expert, M&A deal-maker, serial entrepreneur and angel investor
- Founder and CEO of Venionaire (Group), incl. Venionaire Investment GmbH (AIFM)
- Founder and secretary-general of the Business Angel Institute
- President of the European Super Angels Club
- Expert partner of various accelerators, and partner in venture funds
- Entrepreneur